|本期目录/Table of Contents|

[1]庞永华,陈伟南.人脐带组织间充质干细胞在膝骨关节炎软骨修复中的应用与进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(05):520-524.[doi:10.3969/j.issn.1672-271X.2021.05.016]
　PANG Yong-hua,CHEN Wei-nan.Application and progress of human umbilical cord WJ-MSCs in cartilage repair of knee osteoarthritis[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(05):520-524.[doi:10.3969/j.issn.1672-271X.2021.05.016]
点击复制

人脐带组织间充质干细胞在膝骨关节炎软骨修复中的应用与进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年05
页码:
520-524
栏目:
综述
出版日期:
2021-09-20

文章信息/Info

Title:
Application and progress of human umbilical cord WJ-MSCs in cartilage repair of knee osteoarthritis
作者:
庞永华; 陈伟南
作者单位：214044无锡，安徽医科大学无锡临床医学院（解放军联勤保障部队第九○四医院）骨科[庞永华（医学硕士研究生）、陈伟南]
Author(s):
PANG Yong-hua ;  CHEN Wei-nan
（Department of Orthopaedics，Wuxi Clinical Medical College of Anhui Medical University/the 904th Hosipital of Joint Logistics Support Force, PLA, Wuxi 214044,Jiangsu,China）
关键词:
人脐带; Wharton’s jelly; 间充质干细胞; 膝骨关节炎; 软骨修复
Keywords:
human umbilical cord;  Wharton’s jelly;  mesenchymal stem cells;  knee osteoarthritis;  cartilage repair
分类号:
R684.3
DOI:
10.3969/j.issn.1672-271X.2021.05.016
文献标志码:
A
摘要:
骨性关节炎（OA）是一种常见的慢性关节退行性疾病，影响着一半以上的65岁老年人，常引起关节疼痛、肿胀和僵硬等症状，甚至致残，给患者带来了沉重的经济压力和心理负担。目前临床上的治疗主要包括姑息性治疗和手术干预，然而其效果均不能令人满意。人脐带Wharton胶间充质干细胞（WJ-MSCs）是一种多能干细胞，具有来源较多、获取简单且不涉及伦理问题、较低的免疫原性、较强的增殖和多向分化能力、具有免疫调节能力等优势，最近在人脐带中发现并对其进行了广泛研究，在临床再生工程及早期干预膝关节OA的治疗中展现出广阔的应用前景。文章主要对WJ-MSCs在体外基础实验、动物实验和临床试验中治疗膝骨关节炎软骨修复的相关研究与应用进行综述。
Abstract:
Osteoarthritis (OA) is a common chronic joint degenerative disease, affecting more than half of the 65-year-old, often causing joint pain, swelling, stiffness and other symptoms, and even disability, bringing heavy economic pressure and psychological burden to patients. At present, the clinical treatment mainly includes palliative treatment and surgical intervention, but the results are not satisfactory. Human umbilical cord Wharton glue mesenchymal stem cell (Wharton’s jelly mesenchymal stem cells,WJ-MSCs, (hereinafter referred to as "WJ-MSCs") is a kind of pluripotent stem cell, which has the advantages of many sources, simple acquisition and no ethical problems, low immunogenicity, strong ability of proliferation and multidirectional differentiation, immunomodulatory ability and so on. Recently, it has been found and widely studied in human umbilical cord. It shows a broad application prospect in clinical regeneration engineering and early intervention of knee joint OA. Therefore, this article reviews the research and application of WJ-MSCs in basic experiments, animal experiments and clinical trials in the treatment of cartilage repair of knee osteoarthritis.

参考文献/References:

[1]Musumeci G, Aiello FC, Szychlinska MA, et al. Osteoarthritis in the XXIst century: risk factors and behaviours that influence disease onset and progression[J]. Int J Mol Sci,2015,16(3):6093-6112.
[2]Mamidi MK,Das AK,Zakaria Z, et al. Mesenchymal stromal cells for cartilage repair in osteoarthritis[J]. Osteoarthritis Cartilage,2016,24(8):1307-1316.
[3]Silverwood V,Blagojevic-Bucknall M,Jinks C, et al. Current evidence on risk factors for knee osteoarthritis in older adults: a systematic review and meta-analysis[J]. Osteoarthritis Cartilage,2015,23(4):507-515.
[4]雷光华，王坤正. 骨关节炎诊疗指南(2018年版)解读[J]. 中华骨科杂志,2018,38(12) :716-717.
[5]Jevsevar DS. Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition[J]. J Am Acad Orthop Surg,2013,21(9):571-576.
[6]Bedard NA, DeMik DE, Glass NA, et al. Impact of Clinical Practice Guidelines on Use of Intra-Articular Hyaluronic Acid and Corticosteroid Injections for Knee Osteoarthritis[J]. J Bone Joint Surg Am,2018,100(10):827-834.
[7]Bruyère O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting[J]. Semin Arthritis Rheum,2016,45:S3-S11.
[8]Gugjoo MB, Amarpal,Sharma GT, et al. Cartilage tissue engineering: Role of mesenchymal stem cells along with growth factors & scaffolds[J]. Indian J Med Res,2016,144(3):339-347.
[9]范宏杰，刘利龙. 间充质干细胞的临床应用若干问题[J]. 东南国防医药,2017,19(3) :285-289.
[10]Samsudin EZ, Kamarul T. The comparison between the different generations of autologous chondrocyte implantation with other treatment modalities: a systematic review of clinical trials[J]. Knee Surg Sports Traumatol Arthrosc,2016,24(12):3912-3926.
[11]Taghizadeh RR, Cetrulo KJ, Cetrulo CL. Wharton’s Jelly stem cells: future clinical applications[J]. Placenta,2011, 32(Suppl 4):S311-S315.
[12]McElreavey KD,Irvine AI,Ennis KT, et al. Isolation, culture and characterisation of fibroblast-like cells derived from the Wharton’s jelly portion of human umbilical cord[J]. Biochem Soc Trans,1991,19(1):29S.
[13]Ranjbaran H, Abediankenari S, Mohammadi M, et al. Wharton’s Jelly Derived-Mesenchymal Stem Cells: Isolation and Characterization[J]. Acta Med Iran,2018,56(1):28-33.
[14]Karahuseyinoglu S, Cinar O, Kilic E, et al. Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys[J]. Stem cells,2007,25(2):319-331.
[15]Ramanathan R, Rupert S, Selvaraj S, et al. Role of Human Wharton’s Jelly Derived Mesenchymal Stem Cells (WJ-MSCs) for Rescue of d-Galactosamine Induced Acute Liver Injury in Mice[J]. J Clin Exp Hepatol,2017,7(3):205-214.
[16]Kim DW, Staples M, Shinozuka K, et al. Wharton’s jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications[J]. Int J Mol Sci,2013,14(6):11692-11712.
[17]Weiss ML, Medicetty S, Bledsoe AR, et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson’s disease[J]. Stem cells,2006,24(3):781-792.
[18]Deuse T, Stubbendorff M, Tang-Quan K, et al. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells[J]. Cell Transplant,2011,20(5):655-667.
[19]Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells[J]. Stem cells,2008,26(1):212-222.
[20]Weiss ML, Anderson C, Medicetty S, et al. Immune properties of human umbilical cord Wharton’s jelly-derived cells[J]. Stem cells,2008,26(11):2865-2874.
[21]Ribeiro A, Laranjeira P, Mendes S, et al. Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells[J]. Stem Cell Res Ther,2013,4(5):125.
[22]Bai L, Li D, Li J, et al. Bioactive molecules derived from umbilical cord mesenchymal stem cells[J]. Acta Histochem,2016,118(8):761-769.
[23]Pontikoglou C, Deschaseaux F, Sensebé L, et al. Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation[J]. Stem Cell Rev Rep,2011,7(3):569-589.
[24]Watson N, Divers R, Kedar R, et al. Discarded Wharton jelly of the human umbilical cord: a viable source for mesenchymal stromal cells[J]. Cytotherapy,2015,17(1):18-24.
[25]Harris DT. Umbilical cord tissue mesenchymal stem cells: characterization and clinical applications[J]. Curr Stem Cell Res Ther,2013,8(5):394-399.
[26]Donders R, Vanheusden M, Bogie JF, et al. Human Wharton’s Jelly-Derived Stem Cells Display Immunomodulatory Properties and Transiently Improve Rat Experimental Autoimmune Encephalomyelitis[J]. Cell Transplant,2015,24(10):2077-2098.
[27]Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow[J]. Stem cells,2007,25(6):1384-1392.
[28]Reppel L, Schiavi J, Charif N, et al. Chondrogenic induction of mesenchymal stromal/stem cells from Wharton’s jelly embedded in alginate hydrogel and without added growth factor: an alternative stem cell source for cartilage tissue engineering[J]. Stem Cell Res Ther,2015,6:260.
[29]Aleksander-Konert E, Paduszyński P, Zajdel A, et al. In vitro chondrogenesis of Wharton’s jelly mesenchymal stem cells in hyaluronic acid-based hydrogels[J]. Cell Mol Biol Lett,2016,21:11.
[30]解光越，孙振，刘冠华，等. 人脐带Wharton胶来源间充质干细胞复合藻酸钠水凝胶构建组织工程软骨修复兔膝关节软骨缺损[J]. 中国老年学杂志,2019,39(5):1170-1173.
[31]Liu S, Jia Y, Yuan M, et al. Repair of Osteochondral Defects Using Human Umbilical Cord Wharton’s Jelly-Derived Mesenchymal Stem Cells in a Rabbit Model[J]. Biomed Res Int, 2017 (2017): 8760383.
[32]Wu KC, Chang YH, Liu HW, et al. Transplanting human umbilical cord mesenchymal stem cells and hyaluronate hydrogel repairs cartilage of osteoarthritis in the minipig model[J]. Ci Ji Yi Xue Za Zhi,2019,31(1):11-19.
[33]Park YB, Ha CW, Lee CH, et al. Cartilage Regeneration in Osteoarthritic Patients by a Composite of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells and Hyaluronate Hydrogel: Results from a Clinical Trial for Safety and Proof-of-Concept with 7 Years of Extended Follow-Up[J]. Stem Cells Transl Med,2017,6(2):613-621.
[34]杨孝兵，蒋峰，张帆，等. 脐带间充质干细胞治疗严重膝骨关节炎的对照研究[J]. 中国临床药理学与治疗学,2017,22(3):305-311.
[35]Matas J, Orrego M, Amenabar D, et al. Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase Ⅰ/Ⅱ Trial[J]. Stem Cells Transl Med,2019,8(3):215-224.

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2021-10-11